Quince Therapeutics Inc
quincetx.comQuince Therapeutics Inc (NASDAQ: QNCX) is a clinical-stage biopharmaceutical company developing encapsulated dexamethasone sodium phosphate (eDSP), a drug candidate that uses a patient's own red blood cells to deliver dexamethasone sodium phosphate. The company generates no product revenue as of the 10-K filed April 10, 2026, and has funded operations through financing activities and investment liquidations. As of December 31, 2025, Quince reported a total stockholders' deficit of approximately $35.7 million and used $41.4 million in cash for operating activities in FY2025, up from $31.9 million in FY2024. The company operates through its Italian subsidiary, Quince Therapeutics, S.p.A (formerly EryDel S.p.A.), and carries an unsecured line of credit from the European Investment Bank. In March 2026, Nasdaq notified the company of non-compliance with minimum bid price and minimum market value listing requirements, with a 180-day cure period ending September 14, 2026. Dirk Thye serves as Chief Executive Officer and Chief Medical Officer.
Products & Services
Lead candidate: eDSP (encapsulated dexamethasone sodium phosphate), administered via the eDSP System, an automated combination product that encapsulates dexamethasone sodium phosphate in a patient's own red blood cells. Previously referred to as EryDex. Single-use sterile Treatment Kit is a component of the eDSP System.
Revenue Model
No product revenue disclosed in the filing excerpts. The company is pre-revenue and funds operations through financing activities, including an EIB loan facility, and liquidation of short-term investments.
Customers & Markets
No commercial customers disclosed. End market is rare or chronic inflammatory disease patients requiring corticosteroid therapy, pending regulatory approval in the US and EU. Clinical trials conducted across EU and potentially US jurisdictions.
Geographic Exposure
Operations span the United States and Europe, including Italy through the Quince Therapeutics S.p.A. subsidiary. Regulatory interactions with the FDA and EMA. EIB loan denominated in euros, with a minimum cash covenant of 14.65 million euros ($17.2 million) prior to amendment waivers.
Financial Snapshot
Loading...
